Investing & Trading Blog
Warning From History: Every Time P/E Hits 30, Chaos Follows
Valuation Extremes as Predictors, Not Coincidence When equity markets reach a trailing price-to-earnings (P/E) ratio of 30× earnings, history reveals a pattern:...
Bitcoin Crashed Hard — But Smart Money Might See It Differently
A Violent Correction, An Uneven Narrative In October 2025, Bitcoin suffered one of its sharpest declines in recent memory. Over a single weekend, the cryptocurrency...
Bitcoin just lost more than stocks did in the 1929 market crash. It won’t be the last time.
Bitcoin Just Lost More Than Stocks Did in the 1929 Market Crash. It Won’t Be the Last Time. In a stunning turn of events, Bitcoin’s latest crash erased over 15% of its...
Is Worldline (WLN) the Most Undervalued Fintech in Europe? Why the Smart Money Might Be Buying the Dip
Worldline (WLN.PA) is trading near historic lows after months of panic selling — but smart money sees opportunity. With digital payments growing, governance reforms underway, and sentiment at rock bottom, this could be the start of a powerful turnaround. Here’s why investors are turning bullish again, plus technical zones, target prices, and a clear stop-loss strategy.
Why you should buy this hidden AI crypto ? Alert & Update
Fetch.ai (FET) shows promising upside potential as the AI-powered crypto project rebounds from recent market volatility.
With institutional support and an upcoming token buyback, FET could target $0.80 in the short to mid-term. Learn more about the catalysts driving this bullish outlook at BullishStockAlerts (.) com.
Why add Harmony Biosciences to your watchlist ?
Harmony Biosciences ($HRMY) trades at a depressed valuation despite strong profitability and cash generation. The stock sold off on a recent Fragile X Phase 3 miss, but the core WAKIX franchise and new indications (e.g., PWS) keep revenues and margins robust (~75% GM, ~29% operating margin). Technically, $HRMY is oversold (RSI ~25) and sitting just above 52-week lows ($26.26), creating an asymmetric long setup if $25–26 support holds. Near-term resistance sits at $30–32; a base above $30 opens the path to $36–38 and potentially a re-rating toward consensus targets in the mid-40s. Key risks are pipeline execution and payer dynamics; upside drivers include continued cash flow strength, label expansion, and any positive pipeline or BD catalyst.